Instagram Rolls Out New Features for Personalized Content Discovery and Sharing
PorAinvest
jueves, 7 de agosto de 2025, 4:00 am ET1 min de lectura
ACAD--
The company reported total revenues of $264.6 million for the second quarter, a 9% increase year-over-year, primarily driven by a 7% year-over-year increase in NUPLAZID net product sales to $168.5 million. DAYBUE net product sales also saw a significant 14% year-over-year increase to $96.1 million. CEO Catherine Owen Adams attributed this growth to strong commercial execution and increased engagement from direct-to-consumer campaigns.
Adams highlighted the company's commercial strength, clinical pipeline, and global expansion momentum. The company's R&D strategy includes the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome, with top-line results expected in the fourth quarter of 2025. Additionally, the company completed enrollment in this study and achieved two significant patent litigation wins, securing market exclusivity for NUPLAZID.
The company's financial results also reflect the impact of increased expenditures for both DAYBUE and NUPLAZID in the U.S., including the planned expansion of the DAYBUE commercial team. The company's net income for the second quarter was $26.7 million, a decline from the previous year due to a higher effective tax rate. However, the company's cash and investments totaled $762.0 million as of June 30, 2025.
Acadia Pharmaceuticals is reiterating its 2025 guidance, with the exception of the NUPLAZID net product sales range. The company expects total revenues in the range of $1.045 to $1.095 billion, R&D expenses of $330 to $350 million, and SG&A expenses of $535 to $565 million.
The earnings call scheduled for August 6, 2025, will provide further insights into the company's growth prospects and financial performance.
References:
[1] https://ir.acadia.com/news-releases/news-release-details/acadia-pharmaceuticals-reports-second-quarter-2025-financial
ACADIA Pharmaceuticals has raised its 2025 NUPLAZID guidance to $665M-$690M, driven by strong uptake of DAYBUE. CEO Catherine Owen Adams noted the company's commercial strength, clinical pipeline, and global expansion momentum. The Q2 2025 earnings call highlights the company's growth prospects in the pharmaceutical industry.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced a significant update to its 2025 financial guidance, raising the low end of its NUPLAZID (pimavanserin) net product sales guidance to $665 million to $690 million. This upward revision underscores the company's robust performance in the second quarter of 2025, driven by strong sales of DAYBUE (trofinetide) and a growing clinical pipeline.The company reported total revenues of $264.6 million for the second quarter, a 9% increase year-over-year, primarily driven by a 7% year-over-year increase in NUPLAZID net product sales to $168.5 million. DAYBUE net product sales also saw a significant 14% year-over-year increase to $96.1 million. CEO Catherine Owen Adams attributed this growth to strong commercial execution and increased engagement from direct-to-consumer campaigns.
Adams highlighted the company's commercial strength, clinical pipeline, and global expansion momentum. The company's R&D strategy includes the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome, with top-line results expected in the fourth quarter of 2025. Additionally, the company completed enrollment in this study and achieved two significant patent litigation wins, securing market exclusivity for NUPLAZID.
The company's financial results also reflect the impact of increased expenditures for both DAYBUE and NUPLAZID in the U.S., including the planned expansion of the DAYBUE commercial team. The company's net income for the second quarter was $26.7 million, a decline from the previous year due to a higher effective tax rate. However, the company's cash and investments totaled $762.0 million as of June 30, 2025.
Acadia Pharmaceuticals is reiterating its 2025 guidance, with the exception of the NUPLAZID net product sales range. The company expects total revenues in the range of $1.045 to $1.095 billion, R&D expenses of $330 to $350 million, and SG&A expenses of $535 to $565 million.
The earnings call scheduled for August 6, 2025, will provide further insights into the company's growth prospects and financial performance.
References:
[1] https://ir.acadia.com/news-releases/news-release-details/acadia-pharmaceuticals-reports-second-quarter-2025-financial
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios